Holen Sie sich die Stockscreener-App
3.21
0.62%
-0.02
Handel nachbörslich:
3.21
Schlusskurs vom Vortag:
$3.23
Offen:
$3.21
24-Stunden-Volumen:
17,962
Relative Volume:
0.39
Marktkapitalisierung:
$27.93M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-30.16M
KGV:
-9.4412
EPS:
-0.34
Netto-Cashflow:
$-39.49M
1W Leistung:
-1.23%
1M Leistung:
-0.62%
6M Leistung:
-6.14%
1J Leistung:
+876.57%
1-Tages-Spanne:
$3.21
$3.26
1-Wochen-Bereich:
$3.20
$3.3228
52-Wochen-Spanne:
$0.28
$4.60
Dare Bioscience Inc Stock (DARE) Company Profile
Firmenname
Dare Bioscience Inc
Sektor
Branche
Telefon
858-926-7655
Adresse
3655 NOBEL DRIVE, SAN DIEGO, CA
Vergleichen Sie DARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
3.21 | 27.93M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Dare Bioscience Inc Aktie (DARE) Neueste Nachrichten
Daré Bioscience (NASDAQ:DARE) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience (NASDAQ:DARE) Prepares to Share Corporate Presentation on January 13, 2025 - Defense World
Geode Capital Management LLC Decreases Stock Holdings in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience (NASDAQ:DARE) Share Price Crosses Above Fifty Day Moving Average – Time to Sell? - Defense World
Daré Bioscience Announces New Corporate Presentation - TipRanks
Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Daré Bioscience to Participate in the Women’s Health Series at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Daré Bioscience CEO to Spotlight Women's Health Innovation at J.P. Morgan Healthcare Conference - StockTitan
State Street Corp Lowers Stake in Daré Bioscience, Inc. (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. and ARPA-H Ring the Nasdaq Stock Market Closing Bell - Nasdaq
Daré Bioscience, Inc. and ARPA-H Ring the Closing Bell - Nasdaq
Daré Bioscience (NASDAQ:DARE) Shares Pass Below 200-Day Moving Average – Time to Sell? - Defense World
Daré Bioscience (NASDAQ:DARE) Share Price Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
DARE Stock Touches 52-Week Low at $3.04 Amid Market Challenges - Investing.com
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream Development to Address Female Sexual Arousal Disorder - Defense World
Daré Bioscience to initiate phase 3 study of FSAD treatment - Investing.com
Daré Bioscience Announces Phase 3 Plans for Sildenafil Cream, 3.6%, in the Treatment of Female Sexual Arousal Disorder (FSAD) - The Manila Times
Daré Bioscience Announces Phase 3 Plans for Sildenafil - GlobeNewswire
Daré Bioscience Advances First-Ever FSAD Treatment: Phase 3 Trial Set for Breakthrough Female Sexual Health Drug - StockTitan
Daré Bioscience Announces Publication in Sexual Medicine of - GlobeNewswire
Daré Bioscience's Sildenafil Cream Shows Promising Clinical Data for Female Sexual Health Treatment - StockTitan
Daré Bioscience receives $2.5 million for contraceptive tech By Investing.com - Investing.com Canada
Daré Bioscience receives $2.5 million for contraceptive tech - Investing.com India
DAREDare Bioscience, Inc. Latest Stock News & Market Updates - StockTitan
Daré Bioscience Announces $2.5 Million Grant Funding - GlobeNewswire
Daré Bioscience Announces $2.5 Million Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1 - The Manila Times
Daré Bioscience Advances Revolutionary Wireless Contraceptive Tech With $2.5M Grant Milestone - StockTitan
Dare Bioscience Q3 2024 Earnings Preview - MSN
Analyzing Vistagen Therapeutics (NASDAQ:VTGN) and Daré Bioscience (NASDAQ:DARE) - Defense World
Daré Bioscience, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - MSN
Dare Bioscience (DARE) Upgraded to Buy: Here's What You Should Know - MSN
Dare Bioscience files to sell 2.75M shares of common stocks by selling shareholders - MSN
Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2024 Earnings Call Transcript - Insider Monkey
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Dare Bioscience Inc (DARE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Dare Bioscience Inc (DARE) Quarterly 10-Q Report - Quartzy
Form 10-Q Dare Bioscience, Inc. For: Sep 30 - StreetInsider.com
Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
Daré Bioscience Secures $35.7M in Funding, Cuts R&D Costs by 60% in Q3 Report | DARE Stock News - StockTitan
Daré Bioscience Announces Grant to Support Development of a - GlobeNewswire
Daré Bioscience secures $10.7 million grant from Gates Foundation - Investing.com India
Daré Bioscience secures $10.7 million grant from Gates Foundation By Investing.com - Investing.com UK
Daré Bioscience Lands $10.7M Gates Foundation Grant for Novel Contraceptive Development | DARE Stock News - StockTitan
Daré Bioscience (DARE) Scheduled to Post Earnings on Thursday - Defense World
Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024 - The Manila Times
Daré Bioscience to Host Third Quarter 2024 Financial - GlobeNewswire
Daré Bioscience to Report Q3 2024 Earnings, Host Conference Call November 14 | DARE Stock News - StockTitan
Daré Lands $25M for Women-Centric Pipeline - San Diego Business Journal
Dare BioscienceCatering To Women - RTTNews
Is Bavarian Nordic (BVNRY) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Finanzdaten der Dare Bioscience Inc-Aktie (DARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):